<DOC>
	<DOCNO>NCT00464789</DOCNO>
	<brief_summary>Bazedoxifene/Conjugated Estrogens ( BZA/CE ) investigational drug develop treatment menopause . The purpose trial compare new manufacturing process make BZA/CE current process assess way absorb blood .</brief_summary>
	<brief_title>Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Postmenopausal woman age 35 70 year Body mass index ( BMI ) range 18.0 35.0 kg/m2 body weight great equal 50 kg Healthy determine investigator basis medical history , physical examination , breast gynecologic examination , clinical laboratory test result , vital sign , 12lead electrocardiogram ( ECG ) . Any clinically important active condition gynecologic , cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . History current evidence thrombophlebitis , thromboembolic disorder , coagulopathies . History clinically important drug allergy conjugate estrogen ( CE ) selective estrogen receptor modulators ( SERMs ) .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Postmenopausal</keyword>
</DOC>